{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:32:02Z","timestamp":1720513922443},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T00:00:00Z","timestamp":1471046400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00280-016-3100-0","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T02:46:23Z","timestamp":1471056383000},"page":"745-752","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Feasibility of dose-dense paclitaxel\/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer"],"prefix":"10.1007","volume":"78","author":[{"given":"Seiko","family":"Bun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayu","family":"Yunokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,13]]},"reference":[{"issue":"14","key":"3100_CR1","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1200\/JCO.2006.10.4208","volume":"25","author":"C Bouchardy","year":"2007","unstructured":"Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol Off J Am Soc Clin Oncol 25(14):1858\u20131869. doi: 10.1200\/JCO.2006.10.4208","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1b","key":"3100_CR2","first-page":"611","volume":"27","author":"E Efstathiou","year":"2007","unstructured":"Efstathiou E, Dimopoulos MA, Bozas G, Kastritis E, Moulopoulos LA, Rodolakis A, Vlahos G, Gika D, Papadimitriou C, Bamias A (2007) Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res 27(1b):611\u2013617","journal-title":"Anticancer Res"},{"issue":"29","key":"3100_CR3","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2010.34.1552","volume":"29","author":"KM Fairfield","year":"2011","unstructured":"Fairfield KM, Murray K, Lucas FL, Wierman HR, Earle CC, Trimble EL, Small L, Warren JL (2011) Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(29):3921\u20133926. doi: 10.1200\/JCO.2010.34.1552","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"3100_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ygyno.2014.10.028","volume":"136","author":"WP Tew","year":"2015","unstructured":"Tew WP, Fleming GF (2015) Treatment of ovarian cancer in the older woman. Gynecol Oncol 136(1):136\u2013142. doi: 10.1016\/j.ygyno.2014.10.028","journal-title":"Gynecol Oncol"},{"issue":"6","key":"3100_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.seminoncol.2008.08.007","volume":"35","author":"WP Tew","year":"2008","unstructured":"Tew WP, Lichtman SM (2008) Ovarian cancer in older women. Semin Oncol 35(6):582\u2013589. doi: 10.1053\/j.seminoncol.2008.08.007","journal-title":"Semin Oncol"},{"issue":"9698","key":"3100_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/s0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3\u00a0weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331\u20131338. doi: 10.1016\/s0140-6736(09)61157-0","journal-title":"Lancet"},{"issue":"10","key":"3100_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/s1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14(10):1020\u20131026. doi: 10.1016\/s1470-2045(13)70363-2","journal-title":"Lancet Oncol"},{"key":"3100_CR8","doi-asserted-by":"crossref","unstructured":"Isonishi S, Yasuda M, Takahashi F, Katsumata N, Kimura E, Aoki D, Jobo T, Terauchi F, Tsuda H, Sugiyama T (2008) Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. In: ASCO Annual Meeting; Chicago, IL, USA, 30 May\u20133 June 2008. Abstract 5506","DOI":"10.1200\/jco.2008.26.15_suppl.5506"},{"issue":"11","key":"3100_CR9","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","volume":"24","author":"C Falandry","year":"2013","unstructured":"Falandry C, Weber B, Savoye AM, Tinquaut F, Tredan O, Sevin E, Stefani L, Savinelli F, Atlassi M, Salvat J, Pujade-Lauraine E, Freyer G (2013) Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol Off J Eur Soc Med Oncol ESMO 24(11):2808\u20132813. doi: 10.1093\/annonc\/mdt360","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"issue":"3","key":"3100_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.critrevonc.2007.12.005","volume":"66","author":"S Pignata","year":"2008","unstructured":"Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De VR, Ferrandina G, Gallo C, Perrone F (2008) A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 66(3):229\u2013236. doi: 10.1016\/j.critrevonc.2007.12.005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"3100_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/s1470-2045(14)70049-x","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F (2014) Carboplatin plus paclitaxel once a week versus every 3\u00a0weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396\u2013405. doi: 10.1016\/s1470-2045(14)70049-x","journal-title":"Lancet Oncol"},{"key":"3100_CR12","unstructured":"(2004) Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int J Clin Oncol 9(Suppl 3):1\u201382. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"issue":"3","key":"3100_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transp 48(3):452\u2013458. doi: 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transp"},{"issue":"10","key":"3100_CR14","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1002\/cncr.11375","volume":"97","author":"W Akerley","year":"2003","unstructured":"Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97(10):2480\u20132486. doi: 10.1002\/cncr.11375","journal-title":"Cancer"},{"issue":"3","key":"3100_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/annonc\/mdr297","volume":"23","author":"SM Lichtman","year":"2012","unstructured":"Lichtman SM, Hurria A, Cirrincione CT, Seidman AD, Winer E, Hudis C, Cohen HJ, Muss HB (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol Off J Eur Soc Med Oncol ESMO 23(3):632\u2013638. doi: 10.1093\/annonc\/mdr297","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"issue":"1","key":"3100_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10147-011-0352-x","volume":"18","author":"Y Tanabe","year":"2013","unstructured":"Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18(1):132\u2013138. doi: 10.1007\/s10147-011-0352-x","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"3100_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ygyno.2014.12.021","volume":"136","author":"DM Chase","year":"2015","unstructured":"Chase DM, Huang H, Foss CD, Wenzel LB, Monk BJ, Burger RA (2015) Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology\/Gynecologic Oncology Group study. Gynecol Oncol 136(2):323\u2013327. doi: 10.1016\/j.ygyno.2014.12.021","journal-title":"Gynecol Oncol"},{"issue":"10","key":"3100_CR18","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/jco.2005.04.0543","volume":"24","author":"JJ Lee","year":"2006","unstructured":"Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol Off J Am Soc Clin Oncol 24(10):1633\u20131642. doi: 10.1200\/jco.2005.04.0543","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"3100_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nrclinonc.2014.45","volume":"11","author":"A Errico","year":"2014","unstructured":"Errico A (2014) Gynaecological cancer: MITO-7-a weekly regimen associated with a better quality of life for patients with advanced ovarian cancer. Nat Rev Clin Oncol 11(4):177. doi: 10.1038\/nrclinonc.2014.45","journal-title":"Nat Rev Clin Oncol"},{"issue":"27","key":"3100_CR20","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1200\/jco.2010.32.0796","volume":"29","author":"R Kanesvaran","year":"2011","unstructured":"Kanesvaran R, Li H, Koo KN, Poon D (2011) Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(27):3620\u20133627. doi: 10.1200\/jco.2010.32.0796","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3100_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.03.052","author":"N Joseph","year":"2015","unstructured":"Joseph N, Clark RM, Dizon DS, Lee MS, Goodman A, Boruta D Jr, Schorge JO, Del Carmen MG, Growdon WB (2015) Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol. doi: 10.1016\/j.ygyno.2015.03.052","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3100_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ygyno.2004.12.026","volume":"97","author":"HA Maas","year":"2005","unstructured":"Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen-Heijnen ML (2005) The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 97(1):104\u2013109. doi: 10.1016\/j.ygyno.2004.12.026","journal-title":"Gynecol Oncol"},{"issue":"11","key":"3100_CR23","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/annonc\/mdi368","volume":"16","author":"G Freyer","year":"2005","unstructured":"Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol Off J Eur Soc Med Oncol ESMO 16(11):1795\u20131800. doi: 10.1093\/annonc\/mdi368","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"issue":"25","key":"3100_CR24","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol Off J Am Soc Clin Oncol 29(25):3457\u20133465. doi: 10.1200\/JCO.2011.34.7625","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"3100_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/annonc\/mdl400","volume":"18","author":"O Tredan","year":"2007","unstructured":"Tredan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, Provencal J, Martin J, Stefani L, Pujade-Lauraine E, Freyer G, Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens (2007) Carboplatin\/cyclophosphamide or carboplatin\/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens. Ann Oncol Off J Eur Soc Med Oncol ESMO 18(2):256\u2013262. doi: 10.1093\/annonc\/mdl400","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3100-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T10:27:11Z","timestamp":1568284031000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3100-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,13]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["3100"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3100-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,13]]}}}